Ji, Y.; Calonder, C.; Kirsilä, T.; Burciu, A.; Tisu, M.; Joubert, Y.; Laurent, N.; Hua, E.; Patekar, M.; Drollmann, A.;
et al. Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery System. Pharmaceutics 2023, 15, 2266.
https://doi.org/10.3390/pharmaceutics15092266
AMA Style
Ji Y, Calonder C, Kirsilä T, Burciu A, Tisu M, Joubert Y, Laurent N, Hua E, Patekar M, Drollmann A,
et al. Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery System. Pharmaceutics. 2023; 15(9):2266.
https://doi.org/10.3390/pharmaceutics15092266
Chicago/Turabian Style
Ji, Yan, Claudio Calonder, Tiina Kirsilä, Alis Burciu, Matjaz Tisu, Yolandi Joubert, Nathalie Laurent, Eva Hua, Manmath Patekar, Anton Drollmann,
and et al. 2023. "Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery System" Pharmaceutics 15, no. 9: 2266.
https://doi.org/10.3390/pharmaceutics15092266
APA Style
Ji, Y., Calonder, C., Kirsilä, T., Burciu, A., Tisu, M., Joubert, Y., Laurent, N., Hua, E., Patekar, M., Drollmann, A., & Woessner, R.
(2023). Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery System. Pharmaceutics, 15(9), 2266.
https://doi.org/10.3390/pharmaceutics15092266
